

CURRICULUM VITAE

THOMAS A. ALA, MD

Revised: July, 2018

ADDRESS: Center for Alzheimer's Disease and Related Disorders
Department of Neurology
Southern Illinois University School of Medicine
P.O. Box 19643
Springfield, Illinois 62794-9643

Work Phone: (217) 545-7197
FAX: (217) 545-1903
e-mail: tala@siumed.edu

CURRENT RESEARCH: Caregiving issues in Alzheimer's disease and dementia. Clinical and neuropathological research in Alzheimer disease, dementia with Lewy bodies, vascular dementia, frontotemporal dementia, and other dementing illnesses. Clinical evaluation of new drugs to treat Alzheimer's disease.

APPOINTMENTS:

2017 to date: Professor of Clinical Neurology, Southern Illinois University School of Medicine
2012 to date: Consulting Staff, Abraham Lincoln Memorial Hospital, Lincoln, IL
2007 to date: Interim Director, Center for Alzheimer's Disease and Related Disorders, Springfield, IL
1999 to date: Associate Professor of Clinical Neurology, Southern Illinois University School of Medicine
1999 to date: Active Staff, Department of Neurology, Memorial Medical Center, Springfield, IL
1999 to date: Active Staff, Department of Neurology, St. John's Hospital, Springfield, IL
1987-1999: Active Staff, Department of Neurology, Regions Hospital, St. Paul, MN
1991-1999: Assistant Professor, Department of Neurology, University of Minnesota, Minneapolis, MN
1997-1999: Courtesy Staff, HealthEast Medical Staff, St. John's Northeast Hospital, Maplewood, MN
1988-1996: Acting Director, Memory Disorder Clinic, Regions Hospital, St. Paul, MN
1987-1991: Instructor, Department of Neurology, University of Minnesota, Minneapolis, MN

EDUCATION:

1985-1987: Research Fellow, Alzheimer's Research Center, Regions Hospital, St. Paul, MN.
1982-1985: Neurology residency, University of Minnesota, Minneapolis, MN.
1981-1982: Flexible internship, Hennepin County Medical Center, Minneapolis, MN.
1978-1981: MD degree, University of Minnesota, Minneapolis, MN.
1966-1970: BS degree in Chemical Engineering, Michigan Technological University, Houghton, MI.

HONORS: Michigan Technological University salutatorian 1970; AOA honorary fraternity, University of Minnesota Medical School 1981; Medical Innovators, Sangamon County Medical Society 2009; Kenneth Stark Endowed Chair in Alzheimer's Research 2015; Outstanding Teaching Award, Dept of Neurology 2017-2018.

MEDICAL LICENSURE: Illinois #036-101302, 1999 to date.

BOARD CERTIFICATION: American Board of Psychiatry and Neurology, #28679, 1986.

COMMUNITY SERVICE AND HOBBIES: Nature photography, YoungLife (1996-1999).

OTHER PROFESSIONAL EXPERIENCE:

2016: Active telehealth and/or consulting privileges for the following Central Illinois health care facilities:

Abraham Lincoln Memorial Hospital, Lincoln

Boyd HealthCare Services, Carrollton

Carlinville Area Hospital, Carlinville

Clay County Hospital, Flora

Decatur Memorial Hospital, Decatur

Franklin Hospital District, Benton

Illini Community Hospital, Pittsfield

Mason District Hospital, Havana

Memorial Hospital, Carthage

Pickneyville Hospital, Pickneyville

Shelby Memorial Hospital, Shelbyville

2016 to date: Course Director for the SIU neurology student Individually-Designed Elective.

2013 to date: Course Director for the SIU neurology student Intensive Clinical Experience (sub-internship) elective.

2013: Peer-Reviewer for the 2013 Alzheimer's Association International Research Grant Program.

2012 to date: Medical & Scientific Advisory Committee of the Alzheimer's Association, Greater Illinois Chapter.

2010 to date: Alzheimer's Disease Advisory Committee of the Illinois Department of Public Health, representing a licensed hospital (Memorial Medical Center, Springfield).

2010-2012: Illinois Driver License Medical Advisory Board, Office of the Secretary of State.

2009, 2010: Peer Review Panel, Alzheimer's Disease Research Fund, Illinois Department of Public Health Alzheimer's Disease Advisory Committee.

2008-2009: Public Safety and Law Enforcement SJR 43 Sub-committee of the Illinois Department of Public Health Alzheimer's Disease Advisory Committee.

2008-2009: Center Review SJR 43 Sub-committee of the Illinois Department of Public Health Alzheimer's Disease Advisory Committee.

2006: Reviewer for the Department of Veterans Affairs Cooperative Studies Program.

2003-2009: Associate Editor, *Journal of Alzheimer's Disease*.

1993-1999: Neurological consultant to the Minnesota Board of Medical Practice.

1985-1989: Associate Staff, Dept. of Neurology, Mercy Medical Center, Coon Rapids, MN.

1985-1989: Associate Staff, Dept. of Neurology, North Memorial Medical Center, Robbinsdale, MN.

1970-1978: Technical Service Engineer, 3M Co., St. Paul, MN. Conducted research in lithographic chemistry and field-tested a novel lithographic platemaking system for the newspaper industry.

1969: Development Assistant, Parke-Davis Co., Holland, MI (summer employment).

1968: Engineering Assistant, Panhandle Eastern Pipeline Co., Kansas City, MO (summer employment).

LOCAL COMMITTEES:

2010 to date: SIUSOM (SIU School of Medicine) Year 4 Curriculum Committee.

2005 to date: SIUSOM Springfield Committee for Research Involving Human Subjects (IRB).

2007-2013: SIUSOM Clinical Chairs Committee.

2007-2013: SIUSOM Executive Committee.

2001-2006: SIUSOM Information Management Policy Committee; Electronic Med Records subcommittee.

1993-1999: GRECC Local Advisory Committee, VA Medical Center, Minneapolis.

1994-1999: Univ. of Minn. Medical Student Neurology Externship Program, Course Site Coordinator.

1997-1999: Medical and Scientific Council for the Minnesota Lakes Chapter of the Alzheimer's Assoc.

1994-1995: Regions Hospital, Surgical Intensive Care Unit Committee.

1988-1994: Alzheimer's Advisory Board, University Health Care Center, Minneapolis.

1990-1992: Ramsey Clinic Nominating and Review Committee.

1988-1990: Regions Hospital, Medical Records Committee.

AD HOC JOURNAL REVIEWER: *Alzheimer Disease & Associated Disorders* 2006; *BioMed Central* 2001, 2008; *Clinical Pharmacokinetics* 2006; *CNS & Neurological Disorders-Drug Targets* 2016; *European Journal of Neurology* 2005; *General Hospital Psychiatry* 2009, 2010; *Jacobs Journal of Clinical Case Reports* 2016; *Journal of Alzheimer's Disease* 2003, 2004, 2005, 2008, 2009; *Journal of Geriatric Psychiatry and Neurology* 2006; *Journal of Neurology, Neurosurgery and Psychiatry* 2005, 2007, 2009, 2011, 2012; *Journal of Neuropsychiatry and Clinical Neurosciences* 2001, 2002, 2004, 2005, 2006, 2007, 2008, 2009, 2011 (2), 2013; *Neuroepidemiology* 2009; *Neurology* 2009, 2012, 2014, 2015 (2), 2018; *Neuropsychiatric Disease and Treatment* 2017; *Neuropsychology* 2009; *Neuroscience Letters* 2001; *Pharmaceutical Research* 1992; *Psychiatry Research* 2017; *Western Journal of Nursing Research* 2006.

MEMBERSHIPS: American Academy of Neurology, American Medical Association, Illinois State Medical Society, Sangamon County Medical Society.

GRANTS:

For fiscal years 2004 through 2016, SIU and the SIU Alzheimer's Center have received \$2,325,722 for participating in pharma-sponsored clinical trials for which Dr Ala has been the Principal Investigator.

2017: Memorial Medical Center Foundation Grant No. 2017-49 for SIU-Alzheimer's Conference (November 17 and 18); \$21,029.

1998, 1999: Ramsey Foundation: "Can thioltransferase reverse free radical damage to the human brain muscarinic receptor?," with Dr. William H. Frey; \$25,000 per year.

1998: Ramsey Foundation: "Arachidonic acid inhibition of the muscarinic receptor," with Dr. William H. Frey; \$25,000.

1994, 1995, 1996, 1997: Ramsey Foundation: "A peptide in Alzheimer's brain inhibits antagonist binding to the muscarinic cholinergic receptor," with Dr. William H. Frey; \$20,000 per year (94-96), \$25,000 (97).

1992, 1994, 1995, 1996, 1997: Ramsey Foundation: "Delivery of nerve growth factor to the brain via the olfactory pathway," with Dr. William H. Frey; \$20,000 per year (92-95), \$25,000 per year (96, 97).

1989: Ramsey Foundation: "Nutrition in Alzheimer's disease," with Dr. Edward Ratner; \$20,000.

1986: Ramsey Foundation: "A blood test for Alzheimer's disease," with Drs. Bruce D. Snyder and William H. Frey; \$20,000.

PUBLICATIONS:

Ala T. Donepezil may reduce Insulin-like Growth Factor-1 (IGF-1) levels in Alzheimer's disease. *CNS Neurol Disord Drug Targets*. 2016;15:108-112. PMID: 26553165.

Henderson VW, Ala T, Sainani KI, Bernstein AL, Stephenson BS, Rosen AC, Farlow MR. Raloxifene for women with Alzheimer disease. A randomized controlled pilot trial. *Neurology*. 2015;85:1937-1944. PMID: 26537053.

Jones G, Tabassum V, Zarow GJ, Ala TA. The inability of older adults to recall their drugs and medical conditions. *Drugs Aging*. 2015;32:329-336. PMID: 25829296.

Pyo G, Ala T, Kyrouac GA, Verhulst SJ. A validity study of the Working Group's Autobiographical Memory Test for individuals with moderate to severe intellectual disability. *Res Dev Disabil*. 2011;32:70-74. PMID: 20875945.

Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? *J Alzheimers Dis*. 2010;22:393-399. PMID: 20847431.

Pyo G, Ala T, Kyrouac GA, Verhulst SJ. A pilot study of a test for visual recognition memory in adults with moderate to severe intellectual disability. *Res Dev Disabil*. 2010;31:1475-1480. PMID: 20630702.

Elble RJ, Dubinsky RM, Ala T. Alzheimer's disease and essential tremor finally meet. (Editorial). *Mov Disord*. 2007;22:1525-1527. PMID: 17557351.

Pyo G, Elble RJ, Ala T, Markwell SJ. The characteristics of patients with Uncertain/Mild Cognitive Impairment on the Alzheimer Disease Assessment Scale-Cognitive subscale. *Alzheimer Dis Assoc Disord*. 2006;20:16-22. PMID: 16493231.

Ala TA, Berck LG, Popovich AM. Using the telephone to call for help and caregiver awareness in Alzheimer disease. *Alzheimer Dis Assoc Disord*. 2005;19:79-84. PMID: 15942325.

Ala TA, Berck LG, Popovich AM. Knowledge of personal information and caregiver awareness in Alzheimer's disease. *Am J Alzheimers Dis Other Demen*. 2005;20:119-125. PMID: 15844758.

Ala TA, Doss RC, Sullivan CJ. Reversible dementia: a case of cryptococcal meningitis masquerading as Alzheimer's disease. *Neurology & Cognitive Neuroscience. Review Series*. 2005;1:12-14.

Ala TA, Doss RC, Sullivan CJ. Reversible dementia. A case of cryptococcal meningitis masquerading as Alzheimer's disease. *J Alzheimers Disease*. 2004;6:503-508. PMID: 15505372.

Ala T. With difficult patients, a less definitive diagnosis can be helpful. (Guest Editorial). *Am J Alzheimers Dis Other Demen*. 2004;19:79-80. PMID: 15106387.

Ala TA, Mattson MD, Frey WH II. The clinical diagnosis of Alzheimer's disease without the use of head imaging studies. A cliniconeuropathological study. *J Alzheimers Disease*. 2003;5:463-465. PMID: 14757936.

Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. *Research and Practice in Alzheimer's Disease*. 2003;7:231-235.

- Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. *Int J Geriatr Psychiatry*. 2002;17:503-509. PMID: 12112173.
- Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2001;70:483-488. PMID: 11254771.
- Ala TA, Yang K-H, Sung JH, Frey WH II. Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients. *Acta Neuropathol (Berl)*. 2000;99:511-516. PMID: 10805094.
- Ala TA, Beh GO, Frey WH II. Pure hippocampal sclerosis. A rare cause of dementia mimicking Alzheimer's disease. *Neurology*. 2000;54:843-848. PMID: 10690974.
- Ala TA, Yang K-H, Sung JH, Frey WH II. Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies. *J Neural Transm*. 1999;106:46-57. PMID: 10195334.
- Chen X-Q, Fawcett JR, Rahman Y-E, Ala TA, Frey WH II. Delivery of nerve growth factor to the brain via the olfactory pathway. *J Alzheimers Disease*. 1998;1:35-44. PMID: 12214010.
- Kjome JR, Swenson KA, Johnson MN, Bordayo EZ, Anderson LE, Klevan LC, Fraticelli AI, Aldrich SL, Fawcett JR, Venters HD Jr, Ala TA, Frey WH II. Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid. *J Mol Neurosci*. 1998;10:209-218. PMID: 9770643.
- Ala TA, Yang K-H, Sung JH, Frey WH II. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at time of presentation: a clinicopathologic study. *J Neurol Neurosurg Psychiatry*. 1997;62:16-21. PMID: 9010394.
- Frey WH II, Liu J, Chen X, Thorne RG, Ala TA, Rahman Y-E. Delivery of ¹²⁵I-NGF to the brain via the olfactory route. *Drug Delivery*. 1997;4:87-92.
- Venters HD Jr, Ala TA, Frey WH II. Inhibition of antagonist binding to the human brain muscarinic receptor by vanadium compounds. *Recep Signal Transduct*. 1997;7:137-142. PMID: 9440500.
- Venters HD Jr, Bonilla LE, Jensen T, Garner HP, Bordayo EZ, Najarian MN, Ala TA, Mason RP, Frey WH II. Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation. *Brain Res*. 1997;764:93-100. PMID: 9295197.
- Frey WH II, Najarian MM, Kumar KS, Emory CR, Menning PM, Frank JC, Johnson MN, Ala TA. Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. *Brain Res*. 1996;714:87-94. PMID: 8861612.
- Ala TA, Frey WH II. Validation of the NINCDS-ADRDA criteria regarding gait in the clinical diagnosis of Alzheimer's disease: a clinicopathologic study. *Alzheimer Dis Assoc Disord*. 1995;9:152-9. PMID: 8534414.
- Thorne RG, Emory CR, Ala TA, Frey WH II. Quantitative assessment of protein transport to the rat olfactory bulb following intranasal administration: implications for drug delivery. *Brain Res*. 1995;692:278-82. PMID: 8548316.
- Ala TA, Perfetti PA, Frey WH II. Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurologic symptoms. *J Neuroimmunol*. 1994;53:109-13. PMID: 8051293.
- Chao CC, Ala TA, Hu S, Crossley KB, Sherman RE, Peterson PK, Frey WH II. Serum cytokine levels in patients with Alzheimer's disease. *Clin Diagn Lab Immunol*. 1994;1:433-6. PMID: 8556481.
- Chao CC, Hu S, Frey WH II, Ala TA, Tourtellotte WW, Peterson PK. Transforming growth factor β in Alzheimer's disease. *Clin Diagn Lab Immunol*. 1994;1:109-10. PMID: 7496909.

- Frey WH II, Emory CR, Wiebenga ME, Saxena S, Cardelli D, Ala TA, Tollefson GD. Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. *Brain Res.* 1994;655:153-60. PMID: 7812767.
- Frey WH II, Schmalz JW, Perfetti PA, Norris TL, Emory CR, Ala TA. Silica-ELISA method improves detection and quantitation of minor glycolipid components in lipid mixtures and of other antigens. *J Immunol Methods.* 1993;164:275-83. PMID: 8396603.
- Mendez MF, Ala TA, Underwood KL. Development of scoring criteria for the Clock Drawing Task in Alzheimer's disease. *J Am Geriatr Soc.* 1992;40:1095-9. PMID: 1401692.
- Ala T, Romero S, Knight F, Feldt K, Frey WH II. GM-1 treatment of Alzheimer's disease: a pilot study of safety and efficacy. *Arch Neurol.* 1990;47:1126-30. PMID: 2222246.
- Ala T, Romero S, Knight F, Frey WH II. GM-1 treatment of Alzheimer's disease. In: Wurtman RJ, Corkin SH, Growden JH, and Ritter-Walker E, eds. *Alzheimer's Disease: Advances in Basic Research and Therapies.* Cambridge, MA: Center for Brain Sciences and Metabolism Charitable Trust; 1989;621-7.
- Frey WH II, Ala TA. Recent advances in Alzheimer's disease research. *Progress in Clinical Neurosciences.* 1988;1:287-303.
- Frey WH II, Emory CR, Madsen AM, Rustan TD, Ala TA. Alzheimer's neurofibrillary tangles are labelled by ganglioside monoclonal antibody A2B5. In: Wurtman RJ, Corkin SH, and Growden JH, eds. *Alzheimer's Disease: Advances in Basic Research and Therapies.* Cambridge, MA: Center for Brain Sciences and Metabolism Charitable Trust; 1987;411-5.
- Emory CR, Ala TA, Frey WH II. Ganglioside monoclonal antibody (A2B5) labels Alzheimer's neurofibrillary tangles (NFT). *Neurology.* 1987;37:768-72. PMID: 3574674.

LETTERS:

- Dandapat S, Bhargava P, Ala TA. Familial transient global amnesia. *Mayo Clin Proc.* 2015;90:696-7 (Letter to the Editor). PMID: 25939944.
- Ala TA, Kuhn MJ, Johnson AJ. A case meeting clinical brain death criteria with residual cerebral perfusion. *AJNR Am J Neuroradiol.* 2006;27:1805-6 (Letter to Editor). PMID: 17032844.
- Ala TA. Secondary Alzheimer started by cryptococcal meningitis. *J Alzheimers Disease.* 2005;7:101 (Response to Letter to Editor by H. Rafael). PMID:15851846.
- Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Use of the MMSE to differentiate Alzheimer's disease from dementia with Lewy bodies— response to Larnar. *Int J Geriatr Psychiatry.* 2004;19:1209-10 (Letter to Editor). PMID: 15578752.
- Ala TA. Orientation agnosia in pentagon copying. *J Neurol Neurosurg Psychiatry.* 2002;72:129-30 (Reply to Editor). PMID: 11784847.
- Ala TA, Beh GO, Frey WH II. Hippocampal sclerosis: a rare cause of dementia in the elderly mimicking Alzheimer's disease. *Neurology.* 2000;55:739-740 (Reply to Editor). PMID: 10980757.
- Ala TA, Frey WH II, Clark HB. Posterior cortical atrophy; neuropathologic correlations. *Neurology.* 1996;53:958 (Letter to Editor). PMID: 8859056.
- Ala TA, Frey WH II. The clinical correlates of high-titer IgG anti-GM1 antibodies. *Ann Neurol.* 1994;36:455 (Letter to Editor). PMID: 8080261.
- Pascual-Leone A, Dhuna A, Castillo R, Ala T. Displaced Torkildsen's shunt: an unusual cause of cervical myelopathy. *J Neurol Neurosurg Psychiatry.* 1991;54:654 (Letter to Editor). PMID: 1895134.

ABSTRACTS, POSTERS, ETC.:

- Kyrouac G, Jones G, Tabassum V, Ala T. Older adults have much difficulty recalling their drugs and medical conditions. Poster presented at the 76th Annual Meeting of the Illinois Public Health Association, September 21, 2017, Springfield, Illinois.
- Ala T, Simpson G, Holland M, Tabassum V, Deshpande M, Fifer A. Patients' ability to recall their medical regimens and their caregivers' awareness of their abilities. 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy, Athens, Greece. Retrieved April 15, 2016, from http://www.siumed.edu/cpd/alzheimer/pdf/abstractbook_2016.pdf (page 146).
- Zec RF, Kohlrus S, Robbs R, Ala T. Effects of age, education, and gender on Trail Making Test Parts A & B in non-demented older adults. Poster presented at the 35th Annual Meeting of the National Academy of Neuropsychology, November 5, 2015, Austin, Texas. *Arch Clin Neuropsychol*. 2015;30:525.
- Ala T. An Alzheimer's disease update. In The Doctors' Two Cents: A blog by members of the Sangamon County Medical Society. The State Journal Register. Springfield, Illinois, October 12, 2015. Retrieved October 13, 2015, from <http://www.sj-r.com/article/20151012/BLOGS/151019908/-1/blogs01>.
- Zec RF, Kohlrus S, Robbs R, Ala T. Effects of age and education on MMSE scores. Poster presented at the 43rd Annual Meeting of the International Neuropsychological Society, February 5, 2015, Denver, Colorado. *J Int Neuropsychol Soc*. 2015;21(Suppl 1):81.
- Heeramun V, Mellikyan A, Chandra S, Lee K, Kulkarni S, Ala T. Confusion in a non alcoholic laryngeal cancer patient. Association of Medicine and Psychiatry Annual Meeting, Chicago, Illinois. October, 2014 (poster won third place in Best Poster competition).
- Ala T. Aphasia: An acquired disorder of language. In The Doctors' Two Cents: A blog by members of the Sangamon County Medical Society. The State Journal Register. Springfield, Illinois, June 2, 2014. Retrieved January 21, 2015, from <http://www.sj-r.com/article/20140527/BLOGS/140529491/0/blogs01>.
- Ala T, Jones G, Tabassum V. The ability of older adult patients with and without cognitive impairment to recall their drugs and their medical conditions. 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland. Retrieved April 3, 2014, from http://www.siumed.edu/cme/alzheimer/pdf/AbstractBook_WEB2014.pdf. (page 128).
- Jones G, Tabassum V, Ala T (mentor for second year medical student). The ability of elderly patients to remember their drugs. 23rd Annual Trainee Research Symposium, Southern Illinois University School of Medicine; April 17, 2013 (presentation only).
- Zec RF, Kohlrus S, Fritz S, Robbs R, Ala T. Comparison of cross-sectional and longitudinal data on animal fluency. *Arch Clin Neuropsychol*. 2013;28:554.
- Zec RF, Fritz S, Kohlrus S, Robbs R, Ala T. Cohort (i.e., generational) effects on animal fluency in older adults. *Arch Clin Neuropsychol*. 2013;28:555.
- Ala T. How “reversible” is the dementia that is associated with vitamin B12 deficiency? 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, Sweden. Retrieved May 25, 2012, from http://www.siumed.edu/cme/alzheimer/pdf/AbstractBook_WEB2012.pdf.
- Bhargava P, Ala T. Does dementia associated with vitamin B12 deficiency respond to treatment? American Academy of Neurology Annual Meeting, New Orleans, Louisiana. Retrieved May 25, 2012, from http://www.abstracts2view.com/aan/view.php?nu=AAN12L_P02_057&terms=.
- Zec, R.F., Kohlrus, S., Fritz, S., Robbs, R., Ala, T. Effects of age, education, gender on “FAS” phonemic word fluency. *J Int Neuropsychol Soc*. 2012;18(Suppl 1):247.
- Zec, R.F., Fritz, S., Kohlrus, S., Robbs, R., Ala, T. Reliable change index scores for FAS phonemic word fluency. *Arch Clin Neuropsychology*. 2012;27:583.

- Jones G. (Ala T. mentor for second year medical student). "Medication awareness study." Mentored Professional Enrichment Experience Presentations, Southern Illinois University School of Medicine; September 7, 2012 (presentation only).
- Uga A, Heeramun V, Pilla T, Bottum K, Ala T. Posterior ischemic optic neuropathy with visual release hallucinations. Association of Medicine and Psychiatry Annual Meeting, Chicago, Illinois. September, 2012.
- Holland M. (Ala T. mentor for third year medical student). "A study of Alzheimer's disease and mild cognitive impairment: Patient knowledge of their medications and medical conditions." 22nd Annual Trainee Research Symposium, Southern Illinois University School of Medicine; April 24, 2012 (presentation only, winning second place honors).
- Zec RF, Fritz S, Kohlrus S, Robbs R, Ala T. Animal word fluency: age effects and reliable change index scores. *J Int Neuropsychol Soc.* 2011;17(Suppl S1):262.
- Zec R, Kohlrus S, Fritz S, Robbs R, Ala T. Reliable change index scores for animal fluency. *Arch Clin Neuropsychology.* 2010;25:533.
- Ala TA, Struble RG. The effect of donepezil on serum IGF-1 levels in Alzheimer's disease: a pilot study. Eleventh International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland; March, 2010.
- Zec RF, Fritz S, Kohlrus S, Markwell SJ, Ala T. Effects of age, education, and gender on animal fluency in older adults. *J Int Neuropsychol Soc.* 2010;16(Suppl S1):16.
- Siddiqui FM, Agrawal BK, Ala T. Disseminated pyomyositis: A rare cause of weakness and muscle tenderness with normal CK and aldolase levels. *Neurology.* 2009;72(Suppl 3):A161.
- Ala TA, Jacob KS. A poll of neurology clinics in rural Illinois regarding the evaluation of Alzheimer disease and the availability of related educational material. Clerkship and Program Directors Conference, American Academy of Neurology Annual Meeting, Seattle, Washington; April 25, 2009.
- Ala T, Kyrouac G. A poll of rural Illinois county health departments regarding the evaluation of Alzheimer disease and the availability of related educational information. 136th American Public Health Association Annual Meeting, San Diego, California. Retrieved October 29, 2008, from <http://apha.confex.com/apha/136am/webprogram/Paper176245.html>.
- Ala TA, Kyrouac GA. A Poll of County Health Departments in Rural Illinois Regarding the Evaluation of Alzheimer's Disease and the Availability of Related Educational Information. Sixty-seventh Annual Illinois Public Health Association Conference, Springfield, Illinois; April 2008.
- Ala TA, Vicari SK, Ghobrial MW, Elble RJ. The Responses of Neuropathologically-Proven Alzheimer Disease Patients to the Cholinesterase Inhibitor Metrifonate. Tenth International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy, Hong Kong; February 2008.
- Kyrouac GA, Ala TA, Elble RJ, Schaver, M, Struble RG. Developing a Network to Provide Quality Alzheimer Care in Rural Communities. Tenth International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy, Hong Kong; February 2008.
- Ala T, Kyrouac G. A Poll of county health departments in rural Illinois regarding the evaluation of Alzheimer's disease and the availability of related educational information. Presented at the 15th Annual Alzheimer's Association Dementia Care Conference in Chicago, Illinois. Retrieved August 27, 2007, from <http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={7165BB33-9DE1-4F5A-BF98-41003371D1DA}&MKey={F0ECBD23-BB1B-4FBA-AE14-6ABA00D1B1D9}&AKey={50E1744A-0C52-45B2-BF85-2A798BF24E02}&SKey={2C59B635-F75C-4198-8299-C70198F07EE6>.
- Ala TA, Jacob KS. A poll of neurology clinics in rural Illinois regarding the evaluation of Alzheimer disease and the availability of related educational material. *Neurology.* 2007;68(Suppl 1):A76.

- Ala T, Vicari S, Ghobrial M, Elble R. Neuropathological study of the response of patients with dementia with Lewy bodies to metrifonate. *Neurobiol Aging*. 2006;27S1:S1.
- Ala TA, Vicari SK, Ghobrial MW, Elble RJ. The response of neuropathologically-proven Alzheimer and dementia with Lewy body patients to metrifonate. In: *Book of Abstracts; Insights, Progress and Perspectives*. Alzheimer's and Parkinson's Diseases 7th International Conference; Sorrento, Italy. Geneva, Switzerland; Kenes International; 2005:137.
- Ala, T, Gyires L, Popovich A. Knowledge of personal information, telephone ability, and caregiver awareness in Alzheimer's disease. *Neurobiol Aging*. 2004;25:S345.
- Ala TA, Doss RC, Sullivan CJ. Reversible Dementia. A case of cryptococcal meningitis masquerading as Alzheimer's disease. *Neurology*. 2004;62(Suppl 5):A127.
- Kyrouac GA, McManus DQ, Elble RJ, Ala TA, Struble RG. Developing a Network to Provide Quality Alzheimer Care in Rural Communities. Eleventh National Alzheimer's Disease Education Conference, Chicago, Illinois; July 2003.
- Gyires L, Popovich A, Ala T (mentor for third year medical student) . "Patient Safety and Caregiver Awareness in Alzheimer's Disease." 13th Annual Trainee Research Symposium, Southern Illinois University School of Medicine; April 16, 2003 (presentation only).
- Zec RF, Ghobrial M, Wang Z, Ala T, Pyo GY, Elble R. Cognitive and MRI findings in an autopsy-confirmed case of Pick's disease nine years prior to death. *J Neuropsychiatry Clin Neurosci*. 2003;15:273.
- Zec RF, Ghobrial M, Wang Z, Ala T, Pyo GY, Burkett N, Elble R. Cognitive, behavioral, and MRI findings in an autopsy-confirmed case of Pick's disease during the incipient stages of dementia nine years prior to death. In: *Early Detection of Alzheimer's Disease: Structural, Functional & Molecular Neuroimaging*. 4th Leonard Berg Symposium. St. Louis, MO: Washington University in St. Louis; 2003:41.
- Zec RF, Markwell S, Pyo G, Elble R, Ala T, McManus D. Variability among three neurologists in assigning diagnoses of Alzheimer's disease to patients in a memory and aging clinic. *Arch Clin Neuropsychol*. 2002;17:738.
- Ala TA, Elble RJ. Neuropsychological features help to distinguish dementia with Lewy bodies from Alzheimer disease. *Neurology*. 2002;58(Suppl 3):A379.
- Ala TA, Wang ZY, Kuhn MJ. There may be a dissociation between clinical brain death and cerebral perfusion: a case report. *Neurology*. 2002;58(Suppl 3):A136.
- Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. The Mini-Mental State examination may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. In: *Programme Book of the 17th International Conference*. Christchurch, New Zealand: Alzheimer's Disease International; 2001:149.
- Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. The Mini-Mental State exam may help in the differentiation of Alzheimer and Lewy body dementias. In: *Ageing Myths, Realities & Management of Alzheimer's Disease. An International (Mini)Symposium to the Millennium 52nd Indian Pharmaceutical Congress*. Hyderabad, India: Indian Pharmaceutical Association; 2000:3.
- Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Patients with dementia with Lewy bodies copy the interlocking pentagons on the Mini-Mental State examination less accurately than patients with Alzheimer disease. *Neurobiol Aging*. 2000;21:S83.
- Ala TA, Beh GO, Frey WH II. Hippocampal sclerosis: a rare cause of dementia in the elderly mimicking Alzheimer's disease. *Neurology*. 1999;52(Suppl 2):A477.
- Ala TA, Frey WH II. A study of white matter pallor as a possible cause of dementia. *Neurobiol Aging*. 1998;19:S233.

- Ala TA, Frey WH II. The prevalence of multi-infarct dementia dementia in patients clinically diagnosed as having Alzheimer's disease: a clinicopathologic study. *Neurology*. 1998;50(Suppl 4):A408.
- Ala TA, Yang K-H, Sung JH, Frey WH II. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at time of presentation: a clinicopathologic study. *Focus on Parkinson's Disease*. 1998;10:82.
- Bordayo EZ, Lagalwar S, Swenson KA, Anderson L, Klevan LC, Fawcett JR, Ala TA, Frey WH II. Effects of arachidonic acid, carotenoids and cannabinoids on the muscarinic receptor. *FASEB J*. 1998;12:A151.
- Chen X-Q, Fawcett JR, Ala TA, Rahman Y-E, Frey WH II. Olfactory route: a new pathway to deliver nerve growth factor to the brain. *Neurobiol Aging*. 1998;19:S259.
- Mattson MD, Frey WH II, Ala TA. The clinical diagnosis of Alzheimer's disease without the use of CT or MRI scans. a clinicopathologic study. *Neurology*. 1998;50(Suppl 4):A160.
- Thorne RG, Wilson SJ, Fawcett JR, Ala TA, Frey WH II. Delivery of insulin-like growth factor-1 (IGF-1) to the brain via the olfactory pathway: a possible therapeutic strategy for Alzheimer's disease (AD). *Neurobiol Aging*. 1998;19:S260.
- Ramirez-Lassepas M, Estrada G, Patel D, Tulloch JW, Quinones MR, Ala TA. Non-neurologic predictors of outcome in patients with acute cerebral infarction. *J Neurol Sci*. 1997;150(1):S150.
- Ala TA, Yang K-H, Sung JH, Frey WH II. The majority of dementia patients with the pathological findings of Parkinson's disease at autopsy do not present with parkinsonian symptoms or signs and are not treated for Parkinson's disease during their course. *Neurology*. 1997;48(Suppl 2):A104.
- Frey WH II, Kjome J, Swenson K, Johnson M, Venters HD Jr, Ala,TA. Inhibition of antagonist binding to the human brain muscarinic receptor by arachidonic acid. *FASEB J*. 1997;11:A919.
- Ala TA, Yang K-H, Sung JH, Frey WH II. Hallucinations and signs of Parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at time of presentation. *Neurobiol Aging*. 1996;17:S28.
- Fawcett JR, Chen XQ, Rahman Y-E, Ala TA, Frey WH II. Delivery of NGF to the brain via the olfactory route. *Mol Biol Cell*. 1996;7S:530a.
- Frey WH II, Venters HD Jr, Bonilla LE, Najarian MM, Ala TA, Mason RP. Heme compounds from Alzheimer's brain inhibit muscarinic receptor binding via thiyl radical generation. *Mol Biol Cell*. 1996;7S:647a.
- Venters HJ Jr, Najarian M, Ala TA, Frey WH II. Inhibition of muscarinic receptor binding by pervanadate, orthovanadate, metavanadate and an endogenous inhibitor from Alzheimer's brain. *FASEB J*. 1996;10:A1285.
- Yang K-H, Choi KK, Ala TA, Frey WH II, Sung JH. Neuropathologic analysis of 799 cases of clinically demented patients. *Neurobiol Aging*. 1996;17:S118.
- Frey WH II, Najarian M, Emory C, Ala TA. Oxidized glutathione and endogenous Alzheimer's brain factors inhibit antagonist binding to the muscarinic receptor. *FASEB J*. 1995;9(4, Part II):A682.
- Ala TA, Follmann RK, Frey WH II. Pure multi-infarct dementia rarely mimics Alzheimer's disease throughout its course: a clinicopathologic study. *Neurobiol Aging*. 1994;15(Suppl 1):S99.
- Ala TA, Perfetti PA, Frey WH II. Acute elevations of anti-GM1 antibodies may be neurologically asymptomatic. In: *Gangliosides and Neural Repair. A Satellite Symposium to the 24th Annual Meeting of the American Society for Neurochemistry*. Washington, DC: Fidia Research Foundation; 1993:28.
- Ala TA, Tulloch JW, Frey WH II. Exogenous GM-1 ganglioside may increase auditory P300 latency in Alzheimer's disease. *Neurobiol Aging*. 1992;13(Suppl 1):S133.

- Thorne RG, Perfetti PA, Emory CR, Ala TA, Frey WH II. Quantitative assessment of transneuronal transport to the rat olfactory bulb following intranasal administration of wheat germ agglutinin-horse radish peroxidase (WGA-HRP). *Neurobiol Aging*. 1992;13(Suppl 1):S132.
- Ala T, Romero S, Knight F, Feldt K, Frey WH II. GM-1 treatment of Alzheimer's disease: a pilot study of safety and efficacy. *Core Journals in Clinical Neurology*. 1991;6:10.
- Clements JR, Beitz AJ, Emory CR, Ala TA, Romero S, Knight F, Frey WH II. Ganglioside alterations in Alzheimer's disease and treatment of Alzheimer's disease with GM-1. *Neurobiol Aging*. 1990;11:76.
- Mendez MF, Mastri M, Frey WH II, Ala TA. Diagnostic trends in Alzheimer's disease: clinicopathological evidence in 383 cases from the Ramsey Dementia Brain Bank. *Neurology*. 1990;40(Suppl 1):177.
- Ala T, Romero S, Knight F, Frey WH II. GM-1 treatment of Alzheimer's disease. *Alz Dis Assoc Dis*. 1989;3:3.
- Emory CR, Ala TA, Frey WH II. Ganglioside monoclonal antibody (A2B5) labels Alzheimer's neurofibrillary tangles (NFT). *Fed Proc*. 1986;45:1728.

BOOK CHAPTERS:

- Felthous, AR, Meuser TM, Ala T. Vehicular crashes and the role of mental health clinicians. In: Simon RI, Tardiff K, editors. *Textbook of Violence Assessment and Management*. Washington, DC: American Psychiatric Publishing; 2008:521-536.

INVITED PRESENTATIONS:

- "FTD, TBI, CTE, PPA, ETC." The Many Faces of Dementia, sponsored by the Continuing Education Institute of Illinois. September 27, 2016. Effingham, Illinois.
- "Alzheimer's: Is It in Your Genes?" Annual Research Symposium, Alzheimer's Association Greater Illinois Chapter. October 23, 2015. Oak Brook, Illinois.
- "An Alzheimer's Disease Update (Is there any good news?)." 40/70 Rule Workshop, Home Instead Senior Care. September 16, 2015. Springfield, Illinois.
- "Alzheimer's Research: Get Informed, Get Involved." Alzheimer's Association TrialMatch program. May 20, 2015. Decatur, Illinois.
- "Alzheimer's Research: Get Informed, Get Involved." Alzheimer's Association TrialMatch program. May 5, 2015. Springfield, Illinois.
- "Dementia." Memorial Medical Cntr Prostate Cancer Support Group. January 14, 2015. Springfield. Illinois.
- "Alzheimer's Awareness." Alzheimer's Association. September 5, 2014. Springfield. Illinois.
- "Alzheimer's Awareness." CEU program. Springfield Clinic. May 8, 2014. Springfield. Illinois.
- "Differential Diagnosis of Alzheimer's Disease and Other Dementias." CME program. McDonough District Hospital. April 29, 2014. Macomb, Illinois.
- "A Review of the Latest News in the Diagnosis and Treatment of Alzheimer's Disease." Fall Conference on Alzheimer's & Other Dementias, sponsored by the Alzheimer's Association, Greater Iowa Chapter. November 19, 2013. Davenport, Iowa.
- "Ten Studies in Ten Years." Alzheimer's Research Forum, sponsored by the Alzheimer's Association, Greater Illinois Chapter. June 25, 2013. Decatur, Illinois.
- "Dementia and Intellectual Disability." Aging with Developmental Disabilities Conference, sponsored by the Association on Aging with Developmental Disabilities. May 20, 2013. St. Louis, Missouri.
- "Why Refer Someone to a Specialized Memory Clinic?" 2012 Healthy Aging Conference, sponsored by the Regional Healthy Aging Coalition. October 23, 2012. Urbana, Illinois.

- “Update on Alzheimer's and Treatment Options.” Illinois Guardianship Association Annual Conference. May 10, 2011. Springfield, Illinois.
- “Alzheimer’s Disease and Research Update.” Keynote presentation at the Family Forum Conference on Alzheimer’s Disease and Related Disorders, sponsored by the Alzheimer’s Association. April 24, 2010. Rockford, Illinois.
- “Alzheimer’s Disease and Research Update.” Passavant Area Hospital. October 19, 2009. Jacksonville, Illinois.
- “Diagnosis & Treatment of Alzheimer Disease (from a family practice physician’s perspective).” CME program. Greenville Regional Hospital. May 20, 2009. Greenville, Illinois.
- “Alzheimer’s Disease.” CME program. Passavant Area Hospital. February 3, 2009. Jacksonville, Illinois.
- “An Update on Alzheimer’s Disease.” Presentation included in the “Memory Loss: What’s Normal, What’s Not” program. McDonough District Hospital. October 29, 2008. Macomb, Illinois.
- "Neuropathological Study of the Response of Patients with Dementia with Lewy Bodies to Metrifonate." 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. April 22, 2006. Geneva, Switzerland.
- "Alzheimer's Disease & Other Related Dementias Treatment Updates." OSF Saint Francis Medical Center Grand Rounds. April 20, 2005. Peoria, Illinois.
- "Stroke in the USA. Current Treatment and Research into Free Radical Scavengers." Treatment Progress Conference of Ischemic Stroke, sponsored by Simcere Pharmaceutical Institute. March 3 in Beijing, March 5 in Shanghai, and March 6 in Guangzhou, 2004. China.
- "An Overview of the Non-Alzheimer's Dementias: How Can We Distinguish Them from Alzheimer's Disease?" Keynote address for the professional education conference of the Greater Illinois Chapter of the Alzheimer's Association. March 1, 2002. Schaumburg, Illinois.
- "Dementia with Lewy Bodies: Observations and Diagnosis." Alzheimer's Disease Research Center Tuesday Seminar Series. Washington University. December 6, 2001. St. Louis, Missouri.
- "The Mini-Mental State exam may help in the differentiation of Alzheimer and Lewy body dementias." The Millennium 52nd Indian Pharmaceutical Congress. November 30, 2000. Hyderabad, India.
- "Dementia." Regina Medical Center CME Conference. June 16, 1999. Hastings, Minnesota.
- Respondent for the Citywide Quarterly Geriatric Conference, “Care Strategies for Progressive Dementia.” University of Minnesota Center on Aging. August 13, 1998. St. Paul, Minnesota.
- "Normal Pressure Hydrocephalus." GRECC Grand Rounds. April 15, 1998. Minneapolis, Minnesota.
- "Clinical Aspects of Alzheimer's Disease." American Society for Clinical Laboratory Science Region V Meeting. September 30, 1994. Bloomington, Minnesota.
- “Evaluation of Early Dementia.” Polk County Medical Society. May 16, 1991. Balsam Lake, Wisconsin.
- “Judgment and Safety Issues in Alzheimer’s Disease.” A Geriatric Seminar. Medical Education Committee of Group Health Inc. November 17, 1990. Minneapolis, Minnesota.
- "GM-1 Treatment of Alzheimer's Disease." Update on Cognitive Treatment Strategies in Alzheimer's Disease. 42nd Annual Meeting. Gerontological Society of America. November 18, 1989. Minneapolis.
- “Congophilic Angiopathy.” Neurology Grand Rounds. VA Medical Center. September 23, 1987. Minneapolis, Minnesota.
- “Alzheimer’s Disease.” Annual Convention and Clinical Meeting. Philippine Minnesotan Medical Association. September 12, 1987. Minneapolis, Minnesota.

“Alzheimer’s Disease: Clinical Perspective.” Basic and Clinical Aspects of Alzheimer’s Disease and Epilepsy. Midsummer Mini-symposium. Voyageurs Chapter, Society for Neuroscience. July 15, 1987. Minneapolis, Minnesota.

CLINICAL TRIAL PARTICIPATION:

Current clinical trials

MTAU9937A

2018 to date: "A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of MTAU9937A in patients with prodromal to mild Alzheimer’s disease." US INDs 129270 and 125702; a multi-center trial sponsored by Genentech, Inc.

ABBV-8E12

2017 to date: "A phase 2 multiple dose, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer’s disease." Protocol M15-566; a multi-center trial sponsored by AbbVie, Inc.

SUVN-502

2016 to date: "A phase 2A multicenter, randomized, double-blind, parallel group, 26-week, placebo-controlled study of 50 mg and 100 mg of SUVN-502 in subjects with moderate Alzheimer’s disease currently treated with donepezil hydrochloride and memantine hydrochloride." US IND Number: 116,378; a multicenter trial sponsored by Suven Life Sciences Ltd.

Crenezumab, RO5490245

2016 to date: "A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with prodromal to mild Alzheimer’s disease." US IND 100,839; a multicenter trial sponsored by F. Hoffmann-LaRoche Ltd.

An observational study of Alzheimer's caregivers and their patients

2014 to date: "Caregiver characteristics that may predict when patients with Alzheimer's disease are placed in long-term care facilities," sponsored by the Center for Alzheimer’s Disease and Related Disorders, Southern Illinois University School of Medicine.

[¹⁸F]NAV4694

2013 to date: Principal Investigator in “A Phase III Clinical Trial to Evaluate the Efficacy and Safety of [¹⁸F]NAV4694 PET for Detection of Cerebral β -Amyloid When Compared With Postmortem Histopathology,” US IND Number: 106,157; a multicenter trial sponsored by Navidea Biopharmaceuticals.

Completed clinical trials

[¹⁸F]NAV4694

2013-2018: Principal Investigator in “Beta-Amyloid Imaging with [¹⁸F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer’s Disease (AD) in Subjects with Mild Cognitive Impairment (MCI),” US IND Number: 106,157; a multicenter trial sponsored by Navidea Biopharmaceuticals.

Amyloid scanning

2016-2018: "Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A coverage with evidence development longitudinal cohort study." A multicenter trial directed by the Alzheimer’s Association and sponsored by the American College of Radiology.

T-817MA

2014-2017: Principal Investigator in "A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's Disease (US202)," US IND Number: 70,145; a multicenter trial sponsored by Toyama Chemical Co., coordinated by the Alzheimer's Disease Cooperative Study (ADCS).

AVP-786

2015-2017: "A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type." US IND Number: 124,099; a multicenter trial sponsored by Avanir Pharmaceuticals.

MK-7622

2014-2016: Principal Investigator in "A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects with Alzheimer's Disease," US IND Number: 112,913; a multicenter trial sponsored by Merck Sharp & Dohme Corp.

EVP-6124

2014-2015: Principal Investigator in "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication," US IND Number: 102623; a multicenter trial sponsored by Forum Pharmaceuticals, Inc.

fMRI in Healthy Adults

2014-2015: Co-Principal Investigator in "Consistency of Resting State Networks in Healthy Adult and Elderly Subjects," sponsored by the Center for Alzheimer's Disease and Related Disorders and the Department of Anatomy, Southern Illinois University School of Medicine.

Oral ELND005

2013-2015: Principal Investigator in "A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase II Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease," US IND Number: 115,885; a multicenter trial sponsored by Transition Therapeutics.

IVIg

2012-2013: Principal Investigator in "A phase III randomized, double-blind, placebo-controlled study of the safety and effectiveness of immune globulin intravenous (human), 10% solution (IGIV, 10%) for the treatment of mild to moderate Alzheimer's disease (AD)," Protocol Identifier 161003; a multicenter trial sponsored by Baxter Healthcare and Baxter Innovations GmbH.

Bapineuzumab

2010-2012: Principal Investigator in "A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer disease who are apolipoprotein E ε4 non-carriers," Protocol 3133K1-3000-US; a multicenter trial sponsored by Wyeth Pharmaceuticals.

2010-2012: Principal Investigator in "A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild

to moderate Alzheimer disease who are apolipoprotein E ε4 carriers,” Protocol 3133K1-3001-US; a multicenter trial sponsored by Wyeth Pharmaceuticals.

2008-2012: Principal Investigator in “A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer’s disease,” Protocol No: ELN115727-301; a multicenter trial sponsored by Janssen Alzheimer Immunotherapy.

2008-2012: Principal Investigator in “A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer’s disease,” Protocol No: ELN115727-302; a multicenter trial sponsored by Janssen Alzheimer Immunotherapy.

Raloxifene

2007-2010: Principal Investigator in “Raloxifene in women with AD: randomized controlled trial.” A three-center SIU- and NIH-funded study, initiated by Dr. Victor Henderson.

Valproate

2005-2009: Principal Investigator in "A randomized, double-blind, placebo-controlled clinical trial of valproate to attenuate the progression of Alzheimer's disease (AD)," a multicenter ADCS trial (Alzheimer's Disease Cooperative Study) sponsored by NIH, NIA (National Institutes of Health, National Institute on Aging).

Rasagiline

2006-2008: Principal Investigator in “A multicenter, double-blind, randomized start, placebo-controlled, parallel-group study to assess rasagiline as a disease modifying therapy in early Parkinson's disease," Protocol No. TVP=1012/500 (ADAGIO), a multicenter sponsored by Teva Pharmaceutical Industries, Ltd.

Alzhemed®

2006-2008: Principal Investigator in "A phase III study of the efficacy and safety of Alzhemed™ in patients with mild to moderate Alzheimer's disease," Study No. CL-758007, a multicenter trial sponsored by Neurochem, Inc.

ONO-2506PO

2006-2007: Principal Investigator in "A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease," study protocol ONO-2506POU010, a multicenter trial sponsored by Ono Pharmaceutical Co. Ltd.

High-Dose B Vitamin Supplementation

2004-2006: Principal Investigator in "High dose supplements to reduce homocysteine and slow the rate of cognitive decline in Alzheimer's disease," a multicenter ADCS trial (Alzheimer's Disease Cooperative Study) sponsored by NIH, NIA (National Institutes of Health, National Institute on Aging).

Quetiapine (Seroquel®)

2003-2005: Principal Investigator in "A phase IV study of the treatment of agitation/psychosis in dementia/parkinsonism (TAP/DAP)," a multicenter ADCS trial (Alzheimer's Disease Cooperative Study) sponsored by NIH, NIA (National Institutes of Health, National Institute on Aging).

CoQ₁₀ and GPI 1485

2004-2005: Sub-Investigator in "A multicenter, double-blind, pilot study of CoQ₁₀ and GPI 1485 in subjects with early untreated Parkinson's disease," a multicenter NPDCS trial (NINDS Parkinson's Disease Cooperative Studies) sponsored by the NINDS (National Institute of Neurological Disorders and Stroke).

Minocycline and Creatine

2003-2005: Sub-Investigator in "A multicenter, double-blind, futility study of minocycline and creatine in subjects with early untreated Parkinson's disease," a multicenter NPDCS trial (NINDS Parkinson's Disease Cooperative Studies) sponsored by the NINDS (National Institute of Neurological Disorders and Stroke).

Rivastigmine (Exelon®)

2003-2004: Principal Investigator in "A prospective, 26-week, open-label, single-arm, multi-center study evaluating the efficacy and safety of Exelon® (rivastigmine tartrate) 3-12 mg/day in patients with mild to moderate Alzheimer's disease who are responding poorly to Aricept® (donepezil) treatment," protocol CENA713BUS13; a multicenter trial sponsored by Novartis Pharmaceuticals Corporation.

Galantamine (Reminyl®)

1998-1999: Co-Investigator in "Placebo-controlled evaluation of galantamine in the treatment of Alzheimer's disease: safety and efficacy under a slow-titration regimen," protocol GAL-USA-10; a multicenter trial sponsored by Janssen Research Foundation.

1997-1999: Co-Investigator in "Long-term safety and efficacy of galantamine in the treatment of Alzheimer's disease," protocols GAL-USA-3, GAL-USA-6, and GAL-USA-9, multicenter trials sponsored by Janssen Research Foundation.

1997-1998: Co-Investigator in "Safety and efficacy of galantamine during withdrawal in the treatment of Alzheimer's disease," protocol GAL-USA-5; a multicenter trial sponsored by Janssen Research Foundation.

1997-1998: Co-Investigator in "Galantamine in the treatment of Alzheimer's disease: Flexible dose range trial," protocol GAL-INT-2; a multicenter trial sponsored by Janssen Research Foundation.

1996-1997: Co-Investigator in "Efficacy, tolerability and safety of galantamine in the treatment of Alzheimer's disease," protocol GAL-USA-1; a multicenter trial sponsored by Janssen Research Foundation.

SB 202026

1996-1997: Co-Investigator in "A 48-week double-blind, placebo-controlled, parallel group, fixed dose study of the efficacy, safety and cost-effectiveness of 25µg SB 202026 bid in patients suffering from dementia of the probable Alzheimer's type," a multicenter trial sponsored by SmithKline Beecham Pharmaceuticals.

1995-1997: Co-Investigator in "An open label administration of SB 202026 in patients suffering from probable dementia of the Alzheimer's type," a multicenter trial sponsored by SmithKline Beecham Pharmaceuticals.

1994-1996: Co-Investigator in "A randomized, double-blind, placebo-controlled, dose-ranging study of the efficacy and tolerability of SB 202026 in patients suffering from dementia of the probable Alzheimer's type," a multicenter trial sponsored by SmithKline Beecham Pharmaceuticals.

Donepezil (Aricept®)

1996-1998: Co-Investigator in “A 54-week, randomized, double-blind, placebo-controlled evaluation of the effects of donepezil hydrochloride (E2020) on functional outcomes in patients with Alzheimer’s disease with a staged crossover to open-label donepezil hydrochloride (E2020) treatment,” a multicenter trial sponsored by Eisai America, Inc.

Oral physostigmine

1995-1999: Co-Investigator in “The safety and efficacy of long-term administration of extended-release oral physostigmine in Alzheimer’s disease and senile dementia of the Alzheimer type,” a multicenter open label study sponsored by Forest Laboratories.

1995-1996: Co-Investigator in “The efficacy of extended-release oral physostigmine in Alzheimer’s disease and senile dementia of the Alzheimer type,” a multicenter trial sponsored by Forest Laboratories.

Sabeluzole

1995-1996: Co-Investigator in “Safety of sabeluzole in the long-term treatment of Alzheimer’s disease: An open label extension study,” a multicenter trial sponsored by Janssen Pharmaceutical Corporation.

1994-1996: Co-Investigator in “Clinical evaluation of efficacy and safety of sabeluzole in the treatment of Alzheimer’s disease,” a multicenter trial sponsored by Janssen Pharmaceutical Corporation.

1990-1992: Co-Investigator in “Clinical evaluation of sabeluzole in the treatment of patients with dementia of the Alzheimer type (DAT),” a multicenter trial sponsored by Janssen Pharmaceutical Corporation.

Nimodipine

1991-1999: Co-Investigator in “Nimodipine compassionate use for primary degenerative dementia, program U93-001,” a multicenter trial sponsored by Miles Pharmaceutical Corporation.

1993-1995: Co-Investigator in “A placebo-controlled, randomized, double-blind, multi-center study of the efficacy and safety of nimodipine (BAY e 9736) in patients with probable Alzheimer’s disease,” a multicenter trial sponsored by Miles Pharmaceutical Corporation.

1989-1991: Co-Investigator in “Phase III study of the efficacy and safety of nimodipine in patients with primary degenerative dementia (PDD),” a multicenter trial sponsored by Miles Pharmaceutical Corporation.

TOAST Study (Trial of ORG 10172 in Acute Stroke Treatment)

Albanese MA, Clarke WR, Adams HP Jr, Woolson RF, and the TOAST investigators. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. the program developed for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Stroke. 1994;25:1746-51.

Davis PH, Clarke WR, Bendixen BH, Adams HP Jr, Woolson RF, Culebras A, and the TOAST investigators. Silent cerebral infarction in patients enrolled in the TOAST Study. Neurology. 1996;46:942-8.

GM-1 Ganglioside

1987-1988: Co-Principal Investigator in “A randomized, parallel group, placebo-controlled double-blind trial of GM-1 (IND #21,435) in mild to moderate Alzheimer’s disease,” a single site trial sponsored by Fidia Pharmaceutical Corporation.